Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis

OBJECTIVE To estimate real-world off-label use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes, estimate rates of diabetic ketoacidosis (DKA), and compare them with DKA rates observed in sotagliflozin clinical trials. RESEARCH DESIGN AND METHODS We identified initiators of SGLT2 inhibitors in the Sentinel System from March 2013 to June 2018, determined the prevalence of type 1 diabetes using a narrow and a broad definition, and measured rates of DKA using administrative claims data. Standardized incidence ratios (SIRs) were calculated using age- and sex-specific follow-up time in Sentinel and age- and sex-specific DKA rates from sotagliflozin trials 309, 310, and 312. RESULTS Among 475,527 initiators of SGLT2 inhibitors, 0.50% and 0.92% met narrow and broad criteria for type 1 diabetes, respectively. Rates of DKA in the narrow and broad groups were 7.3/100 person-years and 4.5/100 person-years, respectively. Among patients who met narrow criteria for type 1 diabetes, rates of DKA were highest for patients aged 25–44 years, especially females aged 25–44 years (19.7/100 person-years). More DKA events were observed during off-label use of SGLT2 inhibitors in Sentinel than would be expected based on sotagliflozin clinical trials (SIR = 1.83; 95% CI 1.45–2.28). CONCLUSIONS Real-world off-label use of SGLT2 inhibitors among patients with type 1 diabetes accounted for a small proportion of overall SGLT2 inhibitor use. However, the risk for DKA during off-label use was notable, especially among young, female patients. Although real-word rates of DKA exceeded the expectation based on clinical trials, results should be interpreted with caution due to differences in study methods, patient samples, and study drugs.

[1]  E. Schroeder,et al.  Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data , 2018, Pharmacoepidemiology and drug safety.

[2]  B. Zinman,et al.  Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials , 2018, Diabetes Care.

[3]  K. Brodovicz,et al.  Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review , 2017, BMJ Open.

[4]  I. Harman-boehm,et al.  Diabetic ketoacidosis: clinical characteristics, precipitating factors and outcomes of care. , 2012, The Israel Medical Association journal : IMAJ.

[5]  L. Geiss,et al.  Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality — United States, 2000–2014 , 2018, MMWR. Morbidity and mortality weekly report.

[6]  K. Sullivan,et al.  OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3.1. , 2013 .

[7]  R. Platt,et al.  Automated Detection and Classification of Type 1 Versus Type 2 Diabetes Using Electronic Health Record Data , 2013, Diabetes Care.

[8]  Jingli Lu,et al.  Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials , 2019, Diabetes/metabolism research and reviews.

[9]  T. Oron,et al.  International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors , 2019, Diabetes Care.

[10]  Martijn J Schuemie,et al.  Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. , 2017, Diabetes research and clinical practice.

[11]  P. Lapuerta,et al.  Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.

[12]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[13]  E. Mayer-Davis,et al.  Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study , 2018, Diabetes Care.

[14]  P. Ueda,et al.  Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study , 2018, British Medical Journal.

[15]  C. Koebnick,et al.  Validity of ICD-10-CM codes for determination of diabetes type for persons with youth-onset type 1 and type 2 diabetes , 2019, BMJ Open Diabetes Research & Care.

[16]  M. Phillip,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study , 2018, Diabetes Care.

[17]  R. Beck,et al.  Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. , 2013, The Journal of clinical endocrinology and metabolism.

[18]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[19]  D. O'Neal,et al.  SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. , 2019, The Journal of clinical endocrinology and metabolism.

[20]  P. Lapuerta,et al.  Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study , 2018, Diabetes Care.

[21]  Richard Platt,et al.  The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.

[22]  K. Lee,et al.  Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study , 2018, Diabetes, obesity & metabolism.

[23]  S. Saydah,et al.  Prevalence of Diagnosed Diabetes in Adults by Diabetes Type — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[24]  Richard Platt,et al.  The organizational structure and governing principles of the Food and Drug Administration's Mini‐Sentinel pilot program , 2012, Pharmacoepidemiology and drug safety.

[25]  B. Anderson,et al.  Insulin Omission in Women With IDDM , 1994, Diabetes Care.

[26]  W. Bobo,et al.  Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a tennessee medicaid study , 2011, BMC medical research methodology.

[27]  Zhiguang Zhou,et al.  Incretin-based therapies for patients with type 1 diabetes: a meta-analysis , 2019, Endocrine connections.

[28]  D. Boyle,et al.  The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register , 1997, BMJ.

[29]  C. Mathieu,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial , 2018, Diabetes Care.

[30]  Barbara Evans,et al.  A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.

[31]  H. Rodbard,et al.  The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes , 2016, Diabetes Care.

[32]  R. Henry,et al.  Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes , 2015, Diabetes Care.

[33]  A. Avogaro,et al.  Sodium‐glucose co‐transporter‐2 inhibitors and diabetic ketoacidosis: An updated review of the literature , 2018, Diabetes, obesity & metabolism.

[34]  P. Lapuerta,et al.  HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study , 2018, Diabetes Care.

[35]  S. Schneeweiss,et al.  Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. , 2017, The New England journal of medicine.